Pacific Edge (PEB.NZ) Osake Kurssi
Pacific Edge Kurssi
Liikevaihto on kasvanut 19,7 % vuodessa viimeisten 19 vuoden aikana 21,85 M NZD:een. Pacific Edgen nettomarginaali on nyt −137,0 %, noussut −184,7 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 0,13 NZD, eli ali nykyhintaa 44,6 %. 8 analyytikosta 0 suosittaa ostoa — kokonaiskonsensus on Myy.
Pacific Edge osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Pacific Edge liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Pacific Edge -osakkeesta
The business model of Pacific Edge Ltd is centered around personalized medicine and diagnostic tests. The company specializes in developing and commercializing innovative molecular diagnostic tests that help in the detection and management of cancer. By leveraging advanced technologies, Pacific Edge aims to provide accurate, non-invasive, and cost-effective solutions for early detection and monitoring of various types of cancer. The company's focus on precision medicine enables healthcare professionals to make informed decisions regarding patient treatment, ultimately improving outcomes and reducing healthcare costs. Pacific Edge Ltd is committed to ongoing research and development to expand their portfolio of diagnostic tests and make a positive impact on global cancer care.
Pacific Edge Ltd is primarily active in the healthcare industry.
Some of the main competitors of Pacific Edge Ltd in the market include companies such as Exact Sciences Corp, Genomic Health Inc, and Myriad Genetics Inc.
Pacific Edge Ltd is a New Zealand-based biotechnology company. Established in 2001, Pacific Edge specializes in the discovery and development of diagnostic and prognostic tools for the early detection and monitoring of various cancers. With a focus on urology and the detection of bladder cancer, Pacific Edge has developed a range of proprietary diagnostic tests, including Cxbladder, which has gained recognition worldwide. The company has garnered partnerships and collaborations with various healthcare organizations and research institutes, enabling them to expand their portfolio and global presence. Pacific Edge Ltd continues to innovate and provide cutting-edge solutions in the field of cancer diagnostics.
Pacific Edge Ltd has achieved several significant milestones in its journey. The company successfully developed and commercialized its Cxbladder range of non-invasive, accurate bladder cancer diagnostics. It has established partnerships and distribution agreements with reputed healthcare organizations worldwide, expanding its market reach. Pacific Edge Ltd has also made advancements in its product portfolio, introducing innovative features and improvements to enhance diagnostic accuracy and patient outcomes. Additionally, the company has gained recognition from the medical community, receiving numerous awards and accolades for its groundbreaking diagnostic solutions. Overall, Pacific Edge Ltd has demonstrated relentless commitment to pioneering advancements in bladder cancer diagnostics, solidifying its position as a leader in the field.
Pacific Edge Ltd is primarily present in New Zealand, the United States, Australia, and Canada.
Pacific Edge Ltd represents a commitment to excellence, innovation, and cutting-edge technology within the healthcare industry. With a focus on precision medicine, the company strives to provide accurate and reliable diagnostic solutions for the early detection and monitoring of various cancers. Pacific Edge firmly believes in patient-centric care, ensuring that individuals receive timely and personalized treatment options. The company's corporate philosophy revolves around improving patient outcomes, enhancing healthcare practices, and driving sustainable growth through ongoing research and development. With Pacific Edge Ltd, investors can have confidence in a company that is dedicated to making a positive impact on cancer management worldwide.
Analyytikot asettavat tällä hetkellä Pacific Edge-osakkeelle keskimääräisen tavoitehinnan 0,13 NZD (mediaani: 0,13 NZD), mikä merkitsee −44,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 8 analyytikkoarvioon.
8 analyytikkoa arvioi tällä hetkellä Pacific Edge-osaketta: 0 suosittaa ostoa, 3 pitoa ja 5 myyntiä.
Nykyisellä valuuttakurssilla Pacific Edge-osake noteerataan hintaan 0,12 EUR (0,23 NZD).
Pacific Edge-osake (PEB.NZ) on listattuna 4 pörssissä, muun muassa: ASX (PEB.AX).
Pacific Edge Limited is a New Zealand company specializing in the development and marketing of cancer diagnostics and therapy products. The company operates in three business areas: urology, gynecology, and gastroenterology. In urology, they offer Cxbladder, a non-invasive urine test for diagnosing bladder cancer. In gynecology, they have developed the EndometrialScratch test for early detection of endometrial cancer. And in gastroenterology, they provide the ColonoGuard test, a non-invasive blood-based test for diagnosing colon cancer. Their business model involves international marketing of their products and services, partnering with diagnostic and healthcare companies, and establishing a strong presence in the US market. Their competitive advantages are their unique and effective diagnostic technology and their global market presence. Overall, Pacific Edge aims to improve cancer diagnosis and treatment worldwide.
odotettu liikevaihto Pacific Edge on 11,48 M NZD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
Voittoa ei voida laskea Pacific Edge:lle tällä hetkellä.
P/E-suhdetta ei voida laskea Pacific Edge:lle tällä hetkellä.
Pacific Edge:n hinta-myynti-suhde (P/S) on tällä hetkellä 16,26. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Pacific Edge-osakkeen arvostuskennuslukuna.
Pacific Edge:n Eulpool-laatuscore on 4/10.
Pacific Edge:n ISIN on NZPEBE0002S1. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Pacific Edge:n WKN on A1JQAD. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Pacific Edge:n ticker on PEB.NZ. Tämä pörssinoteeraus käytetään Pacific Edge-osakkeiden kauppaan pörssissä.
Pacific Edge osake
Kaikki tunnusluvut ja syvällinen analyysi Pacific Edge:sta
Meidän osakeanalyysimme Pacific Edge-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Pacific Edge:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: